Morocco Maphar, a 72-year mainstay of the Moroccan pharma industry with both production and distribution arms, has achieved considerable success in recent years, expanding its international network to now reach over 42 big-name partners. General Manager Pierre Labbé outlines the significant footprint of the company – part of the CFAO Group…
Hong Kong Albert Wong of the Hong Kong Science and Technology Parks Corporation (HKSTP) outlines how Hong Kong has developed as an innovation hub, building on its established areas of finance and trading. Wong also discusses the importance of life science companies with HKSTP’s portfolio, the challenges of talent attraction, and the…
UAE Speaking exclusively to PharmaBoardroom, H.E. Dr Noura Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi outlines Abu Dhabi’s rapid progression towards becoming a global life science hub, how the DoH is drawing on international collaborations to help solve the most burning healthcare issues, as well as the transformative…
Global The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. Last year, orphan drugs accounted for more than a third of Europe’s new drug approvals, and the number of gene…
USA With office occupation rates on the slide and the life sciences industry’s demand for lab space on the rise, the repurposing of existing offices into medical laboratories has become an important new asset class, writes Liz Chen, a lab planner at HGA Life Science + Advanced Technology Group’s San Diego…
UAE Ahmed Moustafa outlines the incredible development of the healthcare ecosystem in the UAE driven by a rapid ramping up of the country’s health infrastructure and a willingness on the part of the authorities to enter into partnerships with leading private sector players like Amgen. He also touches on the major…
UAE Ahmad Abu Dahab became the first Middle East employee for Swedish-headquartered haematology, immunology and specialty care player Sobi back in 2012 and now serves as VP for the entire Middle East, Turkey, and Northern Africa region. Abu Dahab explains some of the key trends at play in the rare diseases…
Hong Kong Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory head, Derek Chang, highlights how early access to innovative therapies in the Hong Kong-Greater Bay Area (GBA) can unlock winning…
Global Ever since Novo Nordisk launched Wegovy two years ago, the company has struggled to meet the huge demand for its breakthrough weight loss drug and is yet to make it available in a larger range of markets. Following a recent launch in Germany, Novo Nordisk CEO Lars Fruergaard Jørgensen makes…
India A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory; the government’s revision of Good Manufacturing Practices (GMP) in light of deaths linked to Indian-made cough syrups; Torrent Pharma’s new…
Hong Kong Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and struggling – to better integrate AI into the long and failure-fraught drug discovery process. While AI-enabled drug discovery may not…
Hong Kong One of Asia’s most pre-eminent oncologists, Professor Tony Mok is perhaps best known for discovering the EGFR mutation gene and subsequently developing a targeted therapy that is more precise and personalized than standard chemotherapy. Here, Professor Mok discusses his current research areas of focus, some of the key clinical trial…
See our Cookie Privacy Policy Here
